| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
ML 315 hydrochloride targets CDK (likely CDK1, CDK2, CDK5, or other CDK family members) and DYRK (likely DYRK1A or DYRK1B). These kinases are involved in cell cycle regulation, transcription, neuronal development, and survival. The compound is a selective dual inhibitor that distinguishes it from more selective CDK or DYRK inhibitors.
|
|---|---|
| ln Vitro |
In vitro, ML 315 hydrochloride inhibits the kinase activity of CDK and DYRK with IC50 values of 68 nM and 282 nM, respectively. It is used to investigate the cellular roles of these kinases, including their involvement in cell cycle progression, transcriptional regulation, and neuroprotection. No specific cellular assay data are provided in the sources beyond the IC50 values.
|
| ln Vivo |
No specific in vivo activity data for ML 315 hydrochloride are reported in the search results. However, as a dual CDK/DYRK inhibitor, it is expected to show in vivo efficacy in animal models of cancer (e.g., by inhibiting cell cycle progression and proliferation) and neurological diseases (e.g., by modulating Tau phosphorylation or protecting neurons). These applications are at the exploratory research stage.
|
| Enzyme Assay |
Binding of ML 315 hydrochloride to purified CDK and DYRK kinases is measured by a standard kinase activity assay using a peptide substrate and ATP. The compound is incubated with the kinase, and after adding ATP and substrate, remaining kinase activity is measured. IC50 values are calculated from dose‑response curves, yielding 68 nM for CDK and 282 nM for DYRK.
|
| Cell Assay |
No detailed cellular assay protocol is provided in the search results. In a typical assay, cancer or neuronal cell lines (e.g., HeLa, U2OS, SH‑SY5Y) would be seeded in 96‑well plates and treated with ML 315 hydrochloride at graded concentrations (e.g., 10 nM‑100 microM) for 24‑72 h. Cell viability would be measured by MTT or CellTiter‑Glo. For mechanistic studies, cells would be lysed and analyzed for phosphorylation of CDK and DYRK substrates by Western blot.
|
| Animal Protocol |
No animal experiments for ML 315 hydrochloride are described in the search results. For in vivo evaluation, immunocompromised mice bearing tumor xenografts or transgenic models of neurological disease (e.g., DYRK1A‑overexpressing mice) could be treated orally or intraperitoneally with ML 315 hydrochloride at doses of 10‑100 mg/kg daily for 2‑4 weeks. Tumor volumes, survival, behavioral endpoints, and tissue biomarkers would be assessed.
|
| ADME/Pharmacokinetics |
ML 315 hydrochloride (C1₈H14Cl3N3O2, MW = 410.68) is soluble in DMSO at 50 mg/mL (121.75 mM) with warming to 60degC. For in vivo use, it can be formulated in 10% DMSO / 40% PEG300 / 5% Tween‑80 / 45% saline, or 10% DMSO / 90% corn oil, or other vehicles. The powder should be stored at 4degC sealed and away from moisture. No detailed PK parameters are reported.
|
| Toxicity/Toxicokinetics |
No specific toxicity data for ML 315 hydrochloride are reported in the search results. As a research‑grade kinase inhibitor, it is not intended for human use. Standard safety precautions for laboratory handling (gloves, lab coat, safety goggles) should be followed. No formal toxicological studies have been reported.
|
| References | |
| Additional Infomation |
ML 315 hydrochloride (ML315 hydrochloride) is a selective dual CDK/DYRK inhibitor developed as a chemical probe for studying the biological functions of CDKs and DYRKs in cancer and neurological disease research. It was reported by Coombs et al. (Bioorg Med Chem Lett, 2013). The compound is for research use only and has not entered clinical trials or received regulatory approval. It is valuable for target validation and mechanistic studies.
|
| Molecular Formula |
C18H14CL3N3O2
|
|---|---|
| Molecular Weight |
410.68
|
| Exact Mass |
409.015
|
| CAS # |
2172559-91-8
|
| PubChem CID |
127021037
|
| Appearance |
Solid powder
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
26
|
| Complexity |
435
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1OC2=C(O1)C=C(C=C2)C3=CN=CN=C3NCC4=CC(=CC(=C4)Cl)Cl.Cl
|
| InChi Key |
MNCDEAAKKQCKSX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H13Cl2N3O2.ClH/c19-13-3-11(4-14(20)6-13)7-22-18-15(8-21-9-23-18)12-1-2-16-17(5-12)25-10-24-16;/h1-6,8-9H,7,10H2,(H,21,22,23);1H
|
| Chemical Name |
5-(1,3-benzodioxol-5-yl)-N-[(3,5-dichlorophenyl)methyl]pyrimidin-4-amine;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4350 mL | 12.1749 mL | 24.3499 mL | |
| 5 mM | 0.4870 mL | 2.4350 mL | 4.8700 mL | |
| 10 mM | 0.2435 mL | 1.2175 mL | 2.4350 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
